We understand that some of our patients may be doing this, and if they are, wed like to know about it and still be on their health journey with them, says Kumar
D., Chen, H., & Chen, C
A similar pattern was observed in the SURMOUNT-4 trial for tirzepatide: after participants lost an average of 20.9% of their body weight during a 36-week lead-in phase, those who stopped treatment regained about 14%, while those who continued taking tirzepatide lost an additional 5.5% over the next year
They are not miracle ADHD treatments
An in-depth analysis of the signaling mechanism of GLP-1R in the gutbrain GLP-1R axis is needed to aid in developing smarter new material delivery systems to achieve precise targeting and long-lasting release of GLP-1R agonists
(34) Given the increased risk of sarcopenia, osteoporosis, and frailty in older adults, future research should explore the long-term effects of GLP-1 receptor agonists on musculoskeletal health in this population, alongside their established systemic benefits
